Cingulate Inc. (CING)
Market Closed
30 Jul, 20:00
NASDAQ (CM) NASDAQ (CM) Primary $
4. 76
+0.23
+5.1934%
$
26.68M Market Cap
- P/E Ratio
- Div Yield
123,670 Volume
-3.21 Eps
$ 4.53
Previous Close 
Want to track CING and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?
Cingulate Inc (NASDAQ: CING), a biopharmaceutical firm specializing in innovative ADHD treatments, experienced a remarkable surge in its stock price on Friday, with shares skyrocketing by 115%. This dramatic increase is attributed to the company's recent achievement of securing a European patent for CTx-1301, its flagship ADHD treatment.
Invezz | 1 year ago
